A leading allogeneic T-cell immunotherapy company needed a partner that could navigate the various global advanced therapy medicinal products (ATMP) regulatory requirements and tight timelines of its phase III clinical trial and support its efforts toward commercialization. The company’s end-to-end collaboration with Thermo Fisher allowed for the successful distribution of its clinical supply, and its continued partnership through commercialization provides thousands of patients with the opportunity to try an innovative and potentially life-changing therapy.
Download the case study to learn more.